Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Arcutis Biotherapeutics, Inc.
Bear Case (25th pct.)
-84.9% vs price
Base Case (Median)
-80.4% vs price
Bull Case (75th pct.)
-79.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $4.94 | -80.4% | Medium (25%) |
| Graham Number | $2.68 | -89.3% | Medium (40%) |
| EV/FCF | $5.45 | -78.3% | Medium (20%) |
Based on 3 out of 7 methods, ARQT appears overvalued at the current price of $25.16. The base case fair value of $4.94 implies 80.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.